NCT03049618 - Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2017

Primary Completion Date

September 4, 2024

Study Completion Date

September 4, 2024

Conditions

ALK Gene MutationBRAF Gene MutationEGFR Gene MutationHead and Neck Squamous Cell CarcinomaMetastatic Head and Neck CarcinomaRecurrent Head and Neck CarcinomaRecurrent Non-Small Cell Lung CarcinomaROS1 Gene MutationStage III Non-Small Cell Lung CancerStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

BIOLOGICAL

Recombinant EphB4-HSA Fusion Protein

Given IV

Trial Locations (1)

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER